Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Pericarditis III: Medical Management

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation.

Therapeutic drug monitoring·2025

Same author

HTA Assessment of Clinical-care Pathways: Peritoneal Dialysis Vs Hemodialysis - Content Summary.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2025

Same author

MicroRNA signatures of cancer risk in kidney transplant patients: insights from the COMETA study.

Journal of translational medicine·2025

Same author

Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling Study.

Pharmaceutics·2025

Same author

Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies.

Clinical transplantation·2025

Same author

Guiding the starting dose of the once-daily formulation of tacrolimus in "<i>de novo"</i> adult renal transplant patients: a population approach.

Frontiers in pharmacology·2024

Search research articles

Related Experiment Video

Updated: May 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Belatacept utilization recommendations: an expert position.

Josep M Grinyó¹, Klemens Budde, Franco Citterio

¹Hospital Universitari de Bellvitge, Department of Nephrology, Feixa Llarga, s/n, 08907 Hospitalet de Llobregat, Barcelona, Spain. jgrinyo@bellvitgehospital.cat

Expert Opinion on Drug Safety

|December 5, 2012

Summary

Belatacept offers improved long-term kidney graft function for transplant recipients. This selective immunosuppressant may reduce chronic side effects compared to traditional therapies.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Area of Science:

Nephrology
Immunosuppression
Transplantation

Background:

A need exists for immunosuppressive therapies with improved benefit-risk profiles in renal transplant recipients.
Belatacept, a novel biological agent, is approved for primary maintenance immunosuppression in kidney transplant patients.
Belatacept is indicated for preventing graft rejection in adults receiving renal transplants, in combination with corticosteroids and mycophenolic acid.

Purpose of the Study:

To provide practical recommendations for belatacept use in de novo kidney transplant recipients.
To review safety and efficacy data from Phase II and Phase III clinical trials.
To guide clinicians in optimizing belatacept therapy for renal transplant patients.

Main Methods:

Review of Phase II and Phase III clinical trial data.
Analysis of safety and efficacy outcomes in de novo kidney transplant recipients.
Development of practical recommendations for belatacept administration.

Main Results:

Belatacept treatment is linked to enhanced long-term kidney graft function.
Efficacy and safety data support belatacept's suitability for extended immunosuppression.
Selective targeting by belatacept may mitigate chronic risks associated with calcineurin inhibitors and steroids.

Conclusions:

Belatacept represents a valuable option for preventing kidney allograft rejection.
The drug's long-term safety and efficacy profile makes it suitable for maintenance immunosuppression.
Further research is needed to determine optimal belatacept dosing regimens.